Indian Drug Maker Gains a Manufacturing Toehold in the U.S.

Mumbai-based Lupin Limited (NSE: LUPIN.NS) produces a wide range of branded and generic formulations and APIs globally. Last week it paid $880 million for bought GAVIS Pharmaceuticals LLC and a subsidiary, Novel Laboratories. The acquisition enhances Lupin’s scale in the U.S. generic market and broadens its pipeline in dermatology, controlled substance products and other high-value and niche generics. Gavis had sales of $96 million in FY 2014 and currently has 66 ADA filings pending approval with the FDA, and a pipeline of more than 65 products under development. Its New Jersey-based manufacturing facility is Lupin’s first manufacturing site in the United States



Leave a Reply

Your email address will not be published. Required fields are marked *